Who we are

  • company image 01
  • Upon injury or infection, prokaryotic and/or eukaryotic cells release plethora of disorganized denatured molecules into tissue microenvironment.

    Many of them are water-insoluble, that clog capillaries, incur damages of cellular membrane and disturb tissue homeostasis.

    The water-insoluble molecules in living organisms need to be removed as soon as they appear in tissues.

    If not, they cause deleterious inflammation.

    Hydrophobicity : an ancient damage-associated molecular pattern that initiates innate immune responses SY Seong, P Matzinger - Nature Review Immunology, 2004

  • company image 02
  • In the beginning, life on earth was created in the water.

    The battle between water-soluble and insoluble substances began when the lives advanced to the land.

    Water-insoluble molecules are the origin of foe.

    The immune system has piggy-backed on the system devastating water-insoluble aggregates.

    We study immunology and inflammation, taking biological solubility at the center of intricate immunological balance.

What we do

  • company image 03 company mo image 03
  • New Approach to Inflammatory Diseases (Small Molecule)
    Based on deep understanding of DAMPs (Damage Associated Molecular Patterns)
    Targeting multi-modal, complex inflammatory diseases
    Developing immune modulating molecules with strong efficacy and excellent safety profiles
    Next Generation NanoMAb® Technology
    Based on a wide array of nanobody libraries from immunized camelid
    Focusing on new antigen targets
    Developing nanobody-based cancer therapeutics with high affinity and low immunogenicity
    From bispecific nanobodies to genetically conjugated Nanotoxin®
    High-throughput cell line development
    Targeted integration into hot-spot chromatin structure
    Multi-targeting with stable protein structure

People

  • Seung-Yong Seong, M.D., Ph.D.

    Founder and Chief Executive Officer

    • Seung-Yong Seong image
    • Seoul National University, College of Medicine, M.D., Ph.D.
      Professor, Chair of Microbiology and Immunology, Seoul National University, College of Medicine
      Director(former), Wide River Institute of Immunology, Seoul National University
      Chief Editor, World Journal of Immunology
      Major publications as a corresponding author

      ‘Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune response’ (Nature Reviews Immunology, 2004)

      ‘Multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy’ (Nature Nanotechnology, 2011)

  • Seon-Ae Han, Ph.D.

    Chief Technology Officer & Chief Development Officer / Global R&D Center

    • Seon-Ae Han image
    • University of Tokyo, College of Pharmacy, Ph.D.
      Ewha Woman’s University, College of Pharmacy, MSc.
      Managing Director of R&D Center, Sinsin Pharmaceutical Co., Ltd.
      Director, new drug development, Reyon Phamaceutical Co., Ltd.
      General manager, regulatory affairs and drug development, Bukwang Pharmaceutical Co., Ltd.
      Senior manager, drug development, Dongwha Pharmaceutical Co., Ltd.
      Principal research scientist, Mogam Biotechnology Research Institute
  • Jeong-Tae Kim, MBA

    Chief Operating Officer

    • Jeong-Tae Kim image
    • University of Michigan, Ann Arbor, MBA
      Yonsei University, BA
      CEO, SK Plasma Co., Ltd.
      VP, business development/strategic planning/licensing, SK Chemicals Life Science
      CEO, SK Eurochem
      Senior consultant, Ernst & Young Consulting Co.
      Manager, international business, Kolon International Co.
  • Jung-Seob Kim, Ph.D.

    Head of Nanobody Research

    • Jung-Seob Kim image
    • Seoul National University, Interdisciplinary Program of Agricultural Biotechnology, Ph.D.
      Seoul National University, College of Agricultural Chemistry, MSc.
      Senior manager, cell line engineering/R&D planning, GC Pharma
      Adjunct professor, Department of Biotechnology, The Catholic University of Korea
      Chief researcher, rare disease/protein engineering, Mogam Institute for Biomedical Research
  • Song-Jin Lee, Ph.D.

    Head of R&D Planning & Small Molecule Research

    • Song-Jin Lee image
    • Seoul National University, College of Pharmacy, Ph.D.
      Kangwon National University, College of Pharmacy, MSc.
      Senior manager, technology transfer & manufacturing oversight, CJ Healthcare
      Head of drug evaluation center, CJ Cheiljedang
      Senior manager, clinical development/R&D strategy, YUHAN
  • Sang-Beum Lee, Ph.D.

    Chief Scientist

    • Sang-Beum Lee image
    • Gangneung-wonju National University, molecular biology, Ph.D.
      University of Hawaii at Manoa, Post-Doc.
      Wide River Institute of Immunology, Seoul National University, Post-Doc.
  • Hyun-Mi Park, Ph.D.

    Principal Researcher

    • Hyun-Mi Park image
    • Kangwon National University, Biological Sciences, Biochemistry, Ph.D.
      Wide River Institute of Immunology, Seoul National University, Post-Doc.
  • Hoi-Kwon Jung

    Chief Financial Officer

    • Hoi-Kwon Jung image
    • Sogang University, Business Administration
      Certified Public Accountant (KICPA)
      Director, business management, Huayi Brothers Korea Co., Ltd.
      Manager, IPO department, Hyundai Securities Co., Ltd.
      Accountant, Assurance department, EY Hanyoung Assurance

Getting together